Isgrò Gianmarco, Rogers Alistair, Veeratterapillay Rajan, Rix David, Page Toby, Maestroni Umberto, Bertolotti Lorenzo, Pagnini Francesco, Martini Chiara, De Filippo Massimo, Ziglioli Francesco
Department of Urology, James Cook University Hospital, Middlesbrough TS4 3BW, UK.
Department of Urology, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK.
J Clin Med. 2023 Dec 20;13(1):31. doi: 10.3390/jcm13010031.
(1) Background: In the last decade, the number of detected renal cancer cases has increased, with the highest incidence in Western countries. Although renal biopsy is reported as a safe procedure, it is not adopted in all centres. As it is not possible to accurately distinguish benign tumours using imaging, this may lead to overtreatment. Most of the cancer detected on imaging is treated by surgery, radiofrequency ablation (RFA), or cryotherapy. (2) Methods: This was a single-centre retrospective study of 225 patients studied preoperatively with ultrasound (US)/CT-guided renal biopsy, with the aim of supporting clinical management. Decisions regarding the biopsy were based on either MDT indication or physician preference. US-guided renal biopsy was the first option for all patients; CT-guided biopsy was used when US-guided biopsy was not feasible. The efficacy of renal biopsy in terms of diagnostic performance and the concordance between biopsy results and definitive pathology were investigated. Additionally, adverse events related to the biopsy were recorded and analysed. Data collected throughout the study were analysed using binary logistic regression, Fisher's exact test, and Pearson's chi-square test to investigate possible correlations between post-procedural complications and the size of the lesion. (3) Results: Renal biopsy was not diagnostic in 23/225 (10.2%) patients. A CT-guided approach was necessary in 20/225 patients after failure of US-guided biopsy. The complication rate of renal biopsy was 4.8% overall-all Clavien grade I and without any serious sequelae. Interestingly, complications occurred in patients with very different sizes of renal cell carcinoma. No correlation between complications and anticoagulant/antiplatelet drugs was found. No seeding was reported among the patients who underwent partial/radical nephrectomy. (4) Conclusions: Renal biopsy was shown to be safe and effective, with a high concordance between biopsy results and definitive pathology and a low rate of complications. The use of a CT-guided approach whenever the US-guided approach failed improved the diagnostic performance of renal biopsy.
(1) 背景:在过去十年中,肾癌的检出病例数有所增加,西方国家发病率最高。尽管肾活检被报道为一种安全的操作,但并非所有中心都采用。由于无法通过影像学准确区分良性肿瘤,这可能导致过度治疗。影像学检查发现的大多数癌症通过手术、射频消融(RFA)或冷冻治疗。(2) 方法:这是一项单中心回顾性研究,对225例术前接受超声(US)/CT引导下肾活检的患者进行研究,目的是支持临床管理。活检决策基于多学科团队(MDT)指征或医生偏好。US引导下肾活检是所有患者的首选;当US引导下活检不可行时使用CT引导下活检。研究了肾活检在诊断性能方面的有效性以及活检结果与最终病理之间的一致性。此外,记录并分析与活检相关的不良事件。使用二元逻辑回归、Fisher精确检验和Pearson卡方检验对整个研究过程中收集的数据进行分析,以研究术后并发症与病变大小之间的可能相关性。(3) 结果:225例患者中有23例(10.2%)肾活检未能明确诊断。225例患者中有20例在US引导下活检失败后需要采用CT引导方法。肾活检的总体并发症发生率为4.8%——均为Clavien I级,无任何严重后遗症。有趣的是,不同大小的肾细胞癌患者均出现了并发症。未发现并发症与抗凝/抗血小板药物之间存在相关性。接受部分/根治性肾切除术的患者中未报告种植转移。(4) 结论:肾活检被证明是安全有效的,活检结果与最终病理之间具有高度一致性,并发症发生率低。当US引导方法失败时使用CT引导方法可提高肾活检的诊断性能。